Articles tagged with Chemotherapy
Researchers developed nanoparticles to transport Gemcitabine directly into tumors, increasing efficacy and sparing healthy cells. The approach shows potential to treat pancreatic carcinomas more accurately and with reduced side effects.
Experts call for urgent measures to address discrimination against patients fleeing war or conflict zones, those with serious mental illnesses, and frail elderly patients. Guidelines for treating advanced breast cancer should prioritize patient preferences and involve multidisciplinary care teams.
Patients with breast cancer in conflict zones face significant barriers to treatment, including lack of standard procedures and funding for rebuilding capacity. This results in many patients being diagnosed with advanced breast cancer, often with limited palliative care options.
Researchers discovered narrow-spectrum Wnt signaling inhibitors can suppress breast cancer tumors and reduce chemo-resistant cells in mice. The treatment, derived from a bacterial toxin, targets specific receptors to minimize bone density side effects.
Patients with HER2-positive breast cancer that has spread to other parts of the body survive for longer if treated with pyrotinib. The new drug targets proteins involved in HER2-positive breast cancer and shows a 22% reduction in risk of death compared to lapatinib.
New research suggests that vitamin D supplements can reduce the risk of peripheral neuropathy in patients undergoing paclitaxel treatment. The study found that patients with vitamin D deficiency were more likely to experience severe neuropathy, and that inducing vitamin D deficiency caused similar symptoms in a mice model study.
A specific nucleotide metabolite called GTP controls responses to radiation and chemotherapy in an unexpected way. Increasing GTP levels makes cells resistant to treatment, while lowering them makes cells more sensitive.
A UCLA-led study shows datopotamab deruxtecan, a Trop-2 directed antibody-drug conjugate, significantly improves progression-free survival in patients with metastatic non-small cell lung cancer. The treatment primarily benefits patients with non-squamous tumors, reducing disease progression and improving overall survival.
New study reveals that microtubule poisons effectively treat cancer by causing abnormal cell division, leading to tumor cell death. The findings contradict decades-long assumptions about the mechanism of action of these drugs.
A clinical trial has shown that combining chemotherapy with immunotherapy nivolumab significantly improved outcomes in patients with advanced bladder cancer. The study found nearly twice as many patients with no evidence of disease after treatment, and a median complete response of 37.1 months.
A new study from Columbia University Irving Medical Center suggests that chemotherapy-induced cognitive impairment, or 'chemobrain', may be caused by an excess of calcium floating around inside cells. The research could lead to new treatments to restore cognition in patients experiencing symptoms.
Researchers developed a nanotechnology method to deliver medication through the blood-brain barrier, overcoming its selectivity and expanding therapeutic options for glioblastoma treatment. The technique demonstrated improved tumor shrinkage and survival rates in mice, paving the way for further preclinical studies.
A new study published in JNCCN found that intensive local-regional treatment to remove as much tumor as possible did not significantly impact overall quality of life for patients with metastatic colorectal cancer. However, the treatment was associated with a higher risk of adverse events.
Researchers discovered the STAT3 signaling pathway as a potential target for treating H3K27M-mutant diffuse midline gliomas (DMGs), a uniformly lethal central nervous system malignancy. The current standard of care, including palliative radiation and chemotherapy, remains ineffective in this disease.
A VHIO-led study has identified DPPA3 as a regulator of dormant cancer cells and chemoresistance in colorectal cancer. High levels of DPPA3 are found to predict disease relapse, while HIF1 is proposed as a potential therapeutic target to sensitize CRC cells to chemotherapy.
Research reveals increased sympathetic nerve activity and reduced exercise capacity in patients with heart failure resulting from anthracycline chemotherapy. Sympathetic neural overdrive is associated with skeletal myopathy and decreased cardiac function.
Researchers have developed a new approach to treating invasive bladder cancer, combining chemotherapy and immunotherapy, which may preserve quality of life. In a phase 2 clinical trial, approximately 43% of patients achieved complete response without surgical removal of the bladder.
Researchers at MedUni Vienna discovered that dormant tumor cells surviving chemotherapy can be targeted through the inhibition of P-glycoprotein, opening new possibilities for delaying relapse. This breakthrough could represent a step forward in treating aggressive triple-negative breast cancer, which has limited treatment options and ...
Men with metastatic prostate cancer in Sweden experienced an average survival rate increase of six months after dual treatment was introduced from 2016 onwards. This improvement coincides with the gradual rollout of 'dual treatment', combining standard hormone therapy and chemotherapy or androgen receptor blockers.
A new drug called vorasidenib has been shown to significantly slow tumor growth and extend the average time until tumor growth in patients with grade 2 IDH-mutant gliomas. This breakthrough could offer a first early treatment option for these cancer patients, potentially improving their quality of life.
Researchers explore kinase inhibitors as targeted therapies for specific CRC subsets, offering hope for improved treatment options. Key findings suggest that uncovering essential kinases for tumor growth can lead to more effective treatment strategies in metastatic or later-stage CRC patients.
Researchers developed a novel material that self-assembles into micelle structures targeting cancer cell lysosomes, specifically interacting with Cathepsin B. This leads to dysfunctional lysosomes and apoptotic death of cancer cells. The technology promises a new approach to combat drug resistance in cancer treatment.
Researchers from MedUni Vienna developed a new approach to fighting resistant cell lines in small cell lung cancer by combining two already available therapeutic agents. The study reveals the molecular mechanism underlying therapy resistance and provides a promising basis for research into successful new therapies.
A study published in the Chinese Medical Journal reveals that methotrexate can be an effective treatment for liver cancer with a specific genetic mutation. The drug works by disrupting nucleotide synthesis in cancer cells, making it a promising alternative to current first-line treatments.
A Brown University team developed a hydrogel-based delivery system that balances tumor acidity and increases doxorubicin's effectiveness against cancer cells. Initial lab tests show promising results, paving the way for pre-clinical trials.
Researchers at City University of Hong Kong have developed a new class of near-infrared-activated photo-oxidants that can effectively kill cancer cells without requiring oxygen. The discovery offers a promising direction for developing anti-cancer drugs and could overcome existing limitations of photodynamic therapies.
Researchers found a strong positive correlation between BRD4 overexpression and chemoresistance in ovarian cancer. The study demonstrated that BRD4-L and BRD4-S isoforms play a role in promoting chemotherapy resistance in high-grade serous ovarian carcinoma.
A recent study published in PLOS Biology suggests that chemotherapy injury to surrounding non-cancer cells can awaken dormant breast cancer cells, promoting cancer growth and recurrence. The researchers found that the release of specific cell signaling molecules, G-CSF and IL-6, by injured stromal cells drives this process.
A large-scale international study of childhood cancer survivors found that women who received high-dose doxorubicin chemotherapy without chest radiation have a significantly increased risk of breast cancer before age 40. The researchers are calling for broadening guidelines for breast cancer screening in these patients.
Researchers at Hollings Cancer Center have made a breakthrough in CAR-T-cell therapy by eliminating the need for lymphodepleting chemotherapy, which reduces the risk of severe side effects. In preclinical models, their method showed promising results in controlling cancer and creating memory cells trained on specific proteins.
A subgroup analysis found that patients with an NPM1 mutation had a 48% reduced risk of death compared to those without the mutation. Patients receiving supplementation experienced lower rates of bacterial infections, bleeding, and inflammation during intensive chemotherapy.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
Breast cancer survivors often struggle to take their life-extending medication due to side effects and high costs. A new study found that interventions such as cost-cutting policies, mobile apps, and psychological counseling can increase medication adherence by nearly 1.5 times. Addressing mental health issues, particularly depression,...
Researchers developed a new formulation of doxorubicin that targets cancer cells while reducing cardiotoxicity. The protein-shell encapsulation increases specificity for cancer cells and decreases harm to healthy heart cells.
A new study finds that cost-cutting policy changes, mobile apps, and psychological strategies can increase medication adherence by nearly 1.5 times among breast cancer survivors. The study also highlights the importance of managing side effects through physical therapy, exercise, and behavioral counseling.
Researchers Elzbieta Izbicka and Robert T. Streeper discuss the evolution of cancer drug development, highlighting recent progress and emerging challenges due to environmental factors. They also examine how artificial intelligence may impact future drug development.
Researchers found that certain anti-cancer compounds cause distinct nucleolar shapes and stress, which can be measured using a new classification system. This discovery could lead to improved understanding of why some drugs fail in clinical trials, providing a potential tool for identifying promising drug candidates.
A new targeted treatment called zolbetuximab has been shown to extend survival for patients with advanced gastric or gastroesophageal junction cancer that overexpresses a specific biomarker. The treatment significantly increased progression-free and overall survival, with improved results compared to standard chemotherapy.
Researchers developed SQUID, a computational approach to predict single-cell RNA composition from bulk analysis data. This allows for identification of chemoresistant cells and targeted therapy selection, improving treatment outcomes for patients.
Researchers at St. Jude uncover how ABCG2 protein removes chemotherapies from cells, highlighting a potential path to combat drug resistance. The study identifies key amino acids responsible for this promiscuity and suggests designing inhibitors targeting these sites.
Chronic disease medications impair the body's ability to regulate core temperature, increasing the risk of heat-related illness in elderly patients. Exercise and improved fitness levels can help mitigate these effects, but bodily impairments from chemotherapy and medications may limit exercise capacity.
Researchers at Binghamton University have developed genetically engineered nanovesicles that can target cancer cells more effectively than traditional chemotherapy. These nanocarriers can deliver therapeutic agents directly to the interior of cancer cells, reducing harm to healthy cells and increasing treatment efficacy.
Researchers examine translational studies on peripheral surrogates of tumor burden, including circulating tumor DNA, miRNA, and HPV-specific antibodies, to inform chemotherapy and immunotherapy strategies. These biomarkers show promise as prognostic and predictive markers of response to treatment.
Researchers have made a significant discovery in gene therapy, showing that genetically engineered blood stem cells can be created while still in the bone marrow. This approach eliminates the need for chemotherapy and transplantation of corrected cells, cutting costs and improving access to critical treatments.
Researchers developed innovative techniques to treat challenging cancers and manage therapy side effects. Inhibitors targeting PRMT5, a histone-modifying enzyme, alleviated cisplatin-induced hearing loss, while nano-pills delivered combination drugs to liver cancer cells.
A new study published in JNCCN found that the adoption of clinical research results led to a significant increase in the use of shorter adjuvant chemotherapy periods, with CAPOX becoming more widely used. The study also revealed disparities in treatment patterns, with Black patients being more likely to receive shorter chemotherapy reg...
A study found that breast cancer patients with higher body mass index (BMI) are more likely to experience heart damage, or cardiotoxicity, during chemotherapy. The study suggests that addressing obesity and considering the potential risk of cardiotoxicity requires a comprehensive approach.
Brigham researchers use induced pluripotent stem cells to restore hormone production and fertility in mice with premature ovarian failure. The study shows promise for treating incurable conditions and may lead to new therapies for patients with ovarian failure.
Researchers from Korea University Medicine have discovered a potential therapeutic target for overcoming cisplatin resistance and neuropathic pain in cervical cancer. By inhibiting TRPV1, they found that resistant tumors became vulnerable to cisplatin, improving the outlook for patients.
Scientists identified a process by which enzymes help prevent heart damage in chemotherapy patients. Enzymes normally found in mitochondria move to the nucleus, keeping cells alive. This discovery suggests new methods for testing individual patient responses and potentially preventing heart damage from chemotherapy.
Researchers report a case of a 15-year-old boy with recurrent intrathoracic synovial sarcoma who achieved partial response with BRAF inhibitor Vemurafenib treatment. The study highlights the importance of routine next-generation sequencing to drive treatment choice and investigate BRAF mutations in SS tumors.
The updated guidelines urge the clinical use of validated geriatric assessments (GA) to guide treatments in patients aged 65 and older. This approach often results in de-escalation or reduction of therapies, reducing side effects and improving quality of life without compromising survival odds.
A synoptic report improved the completeness of pretreatment CT reports in patients with advanced ovarian cancer. Involvement of surgically established unresectable or challenging-to-resect disease sites was mentioned in all disease-specific synoptic reports, compared to 37% of simple structured reports.
Researchers at the University of Alberta have discovered a correlation between chemotherapy-induced changes to gut bacteria and unhealthy weight gain in breast cancer patients. The study found that these patients gained abdominal fat and experienced inflammation, with significant changes to their gut microbiome.
Researchers have identified a biomarker called CXCL-9 that can be used to diagnose acute tubulointerstitial nephritis (AIN), a condition causing inflammation of the kidneys. The biomarker can be detected via a simple urine test, potentially reducing the need for kidney biopsies.
Researchers at Moffitt Cancer Center found that higher c-reactive protein levels were associated with greater depression and less physical activity among patients with gynecologic cancers. However, most inflammatory markers were not linked to treatment-related symptoms.
A Mayo Clinic study reveals that minimally invasive surgical procedure staging laparoscopy can identify cancer spread early and determine the stage of pancreatic cancer. The research found a higher risk of cancer spread in patients with certain factors, such as age and tumor markers.
Researchers explore pyroptosis as a potential therapeutic approach for lung cancer treatment. The review highlights the dual role of pyroptosis in tumor progression and negative impact on normal cells. It suggests balancing the contradictory effects of pyroptosis to optimize clinical applications.
Research suggests that glioblastoma cells possess large-scale coordination, allowing them to respond unison to therapies. Disrupting this organization may result in more powerful treatments for brain tumors.
Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.